2026-01-20 - Analysis Report
**Novo Nordisk (NVO) Analysis Report**

**Company Overview**: Novo Nordisk is a Danish global healthcare company specializing in the manufacturing and sale of pharmaceuticals, focusing on diabetes and obesity treatments.

**Return Rate Comparison**

| Ticker | Cumulative Return |
| --- | --- |
| NVO    | 53.30% |
| VOO    | 93.30% |

The current divergence is -40.00, indicating that the cumulative return of NVO is lower than that of S&P 500 by 40.00 percentage points.

**Alpha, Beta Analysis**

| Period | CAGR  | MDD  | Alpha | Beta | Cap(B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 0.0% | 19.0% | -5.0% | 0.8 | 102.4B |
| 2017-2019 | 37.0% | 13.6% | 20.0% | 0.6 | 128.6B |
| 2018-2020 | 1.0% | 12.5% | -20.0% | 0.6 | 155.2B |
| 2019-2021 | 58.0% | 13.0% | 15.0% | 0.6 | 248.8B |
| 2020-2022 | 58.0% | 23.2% | 60.0% | 0.6 | 300.7B |
| 2021-2023 | 87.0% | 23.2% | 86.0% | 0.5 | 459.7B |
| 2022-2024 | 18.0% | 40.5% | -1.0% | 0.5 | 382.2B |
| 2023-2025 | -52.0% | 59.7% | -114.0% | 0.7 | 226.1B |

**Recent Stock Price Fluctuations**

* Close: $62.33
* 5-day SMA: $59.57
* 20-day SMA: $54.41
* 60-day SMA: $50.73

**RSI, PPO Index Indicators and Delta_Previous_Relative_Divergence**

* RSI: 76.91
* PPO: 1.05
* Market Risk Indicator (MRI): 0.80 (Medium Investment)
* Recent (20 days) relative divergence change: 4.70 (+) improving
* 7-day Rank change: 0 (0): flat
* 7-day Dynamic Expected Return change: 0.00 (0): flat
* Expected Return (%): 214.80%

**Recent News & Significant Events**

* 2026-01-19: NVO stock is rising pre-market – what is the Wegovy news driving Novo Nordisk shares?
* 2026-01-16: Eli Lilly vs. Novo Nordisk: Which Is the Better Stock Buy?
* 2026-01-16: Novo's Wegovy Pill Looks A Lot Like Zepbound — In One Week
* 2026-01-16: Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
* 2026-01-19: Novo Nordisk Stock Climbs on Strong Oral Weight Loss Drug Sales
* 2026-01-06: Novo Nordisk: NVO Stock To $100?

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.38 (~Buy)
- Opinions: 11
- Target Price (avg/high/low): 55.98 / 73.41 / 41.63

**Comprehensive Analysis (Summary)**

Based on the provided data, Novo Nordisk's stock has experienced fluctuations, with a recent surge driven by positive news on its Wegovy obesity pill. The company's cumulative return is lower than that of S&P 500, indicating a lower investment return. However, the expected return (%): 214.80% suggests that investing in Novo Nordisk long-term may lead to significant returns. The recent news and significant events indicate a positive sentiment, with analysts recommending a buy. The analyst consensus also supports a buy recommendation, with a target price of $55.98.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.